data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

My Account

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Freight
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

vTv Therapeutics Inc

(NASDAQ:VTVT)

$0.47

0.01[2.17%]

Last update: 4:15PM (Delayed 15-Minutes)
Get Real Time Here

$0.47

0[0.00%]

Open0.469	Close0.478
Vol / Avg.55.865K / 163.415K	Mkt Cap38.297M
Day Range0.450 - 0.490	52 Wk Range0.405 - 1.050

0

Latest News for vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Stock (NASDAQ: VTVT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, August 11, 2023

vTv Therapeutics Q2 EPS $(0.07), Inline
Benzinga Newsdesk - Aug 11, 2023, 4:33PM

Thursday, August 10, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Aug 10, 2023, 9:06AM
Cantex Pharmaceuticals Announces Article Published In npj Breast Cancer Highlighting Potential Role Of RAGE Inhibition To Prevent Metastasis In Triple-Negative Breast Cancer
Benzinga Newsdesk - Aug 10, 2023, 8:34AM

Thursday, July 27, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jul 27, 2023, 5:32PM

Thursday, July 20, 2023

On July 17, vTv Therapeutics Received Nasdaq Notice Approving Request To Extend Co's Period To Regain Compliance With Min Bid Requirement Until Dec 18
Happy Mohamed - Jul 20, 2023, 4:28PM

Thursday, June 22, 2023

Board Member at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM
Director at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM

Friday, June 16, 2023

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment For Cancer-Related Cognitive Decline
Benzinga Newsdesk - Jun 16, 2023, 8:01AM

Thursday, June 01, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jun 1, 2023, 5:39PM
Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pharma
Happy Mohamed - Jun 1, 2023, 10:49AM

Wednesday, May 24, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 24, 2023, 9:06AM
vTv Therapeutics Announces Issuance Of US Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Benzinga Newsdesk - May 24, 2023, 9:04AM

Thursday, April 20, 2023

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19
Benzinga Newsdesk - Apr 20, 2023, 8:07AM

Tuesday, March 07, 2023

HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk - Mar 7, 2023, 4:41AM

Monday, March 06, 2023

vTv Therapeutics Q4 EPS $(0.06), Inline, Sales $9.00K, Same YoY
Michael Horton - Mar 6, 2023, 5:33PM
VTv Therapeutics shares are trading higher after Cantex and the Miami Cancer Institute announced FDA clearance for a clinical trial investigating azeliragon combined with stereotactic radiosurgery for the treatment of brain metastases.
Benzinga Newsdesk - Mar 6, 2023, 8:24AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Benzinga Newsdesk - Mar 6, 2023, 8:03AM

Monday, February 27, 2023

Cantex Receives FDA 'Study May Proceed' Letter For Phase 2 Clinical Trial Of Azeliragon For Treatment Of Unmethylated Glioblastoma
Bill Haddad - Feb 27, 2023, 8:07AM

Tuesday, January 10, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jan 10, 2023, 8:05AM

Monday, January 09, 2023

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Glioblastoma
Benzinga Newsdesk - Jan 9, 2023, 8:01AM

Tuesday, December 13, 2022

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch As Chief Financial Officer Effective Immediately
Benzinga Newsdesk - Dec 13, 2022, 8:16AM

Thursday, December 01, 2022

vTv Therapeutics Board Member Makes $50K Stock Purchase
Benzinga Insights - Dec 1, 2022, 10:01AM

Thursday, November 10, 2022

vTv Therapeutics Q3 EPS $(0.05) Down From $(0.02) YoY
Michael Horton - Nov 10, 2022, 5:26PM

Friday, August 19, 2022

This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
Vandana Singh - Aug 19, 2022, 12:42PM

Wednesday, August 17, 2022

Northland Capital Markets Maintains Outperform on vTv Therapeutics, Raises Price Target to $2
Benzinga Newsdesk - Aug 17, 2022, 10:37AM

Wednesday, July 27, 2022

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Vandana Singh - Jul 27, 2022, 9:28AM
vTv Therapeutics Announces Paul Sekhri As President And Chief Executive Officer
Bill Haddad - Jul 27, 2022, 7:23AM

Monday, July 25, 2022

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Vandana Singh - Jul 25, 2022, 9:20AM
vTv Therapeutics shares are trading higher after the company announced a $10 million investment by CinRx Pharma.
Benzinga Newsdesk - Jul 25, 2022, 8:29AM
vTv Therapeutics Shares Jump On Equity Investment
Vandana Singh - Jul 25, 2022, 8:22AM
11 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 25, 2022, 8:16AM
vTv Therapeutics Announces Investment By CinRx Pharma; CinPax Acquired ~4.15M Shares Of vTv Common Stock For ~$2.41/Share
Benzinga Newsdesk - Jul 25, 2022, 7:08AM

Friday, July 08, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jul 8, 2022, 5:58PM

Wednesday, June 22, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 22, 2022, 5:42PM

Friday, June 17, 2022

vTv Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - Jun 17, 2022, 11:04AM

Tuesday, June 07, 2022

vTv Therapeutics Shares Move Higher; Co Granted Canadian Patent Titled 'TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE'
Benzinga Newsdesk - Jun 7, 2022, 10:49AM

Friday, June 03, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Jun 3, 2022, 8:08AM
Aravive Names Rudy Howard as CFO
Charles Gross - Jun 3, 2022, 7:05AM

Thursday, June 02, 2022

62 Biggest Movers From Yesterday
Lisa Levin - Jun 2, 2022, 6:10AM

Wednesday, June 01, 2022

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet
Lisa Levin - Jun 1, 2022, 2:51PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jun 1, 2022, 1:44PM
Mid-Day Market Update: Dow Dips 200 Points; Tonix Pharmaceuticals Shares Spike Higher
Lisa Levin - Jun 1, 2022, 12:17PM
44 Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Jun 1, 2022, 12:14PM
Benzinga's Brief On Trending Tickers: Salesforce, Mullen Automotive, Digital Turbine And More
AJ Fabino - Jun 1, 2022, 9:32AM
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, June 1, 2022: TSLA, GME, VTVT, ETON, KYMR
Benzinga Newsdesk - Jun 1, 2022, 8:53AM
vTv Therapeutics shares are trading higher after the company announced entry into agreements that include a $25 million investment by G42 Investments.
Benzinga Newsdesk - Jun 1, 2022, 8:51AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jun 1, 2022, 8:08AM
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
Bill Haddad - Jun 1, 2022, 6:56AM

Wednesday, May 18, 2022

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 18, 2022, 8:17AM

1
2
3
4
5
6
7
Next
17

Latest News for vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Stock (NASDAQ: VTVT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, August 11, 2023

vTv Therapeutics Q2 EPS $(0.07), Inline
Benzinga Newsdesk - Aug 11, 2023, 4:33PM

Thursday, August 10, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Aug 10, 2023, 9:06AM
Cantex Pharmaceuticals Announces Article Published In npj Breast Cancer Highlighting Potential Role Of RAGE Inhibition To Prevent Metastasis In Triple-Negative Breast Cancer
Benzinga Newsdesk - Aug 10, 2023, 8:34AM

Thursday, July 27, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jul 27, 2023, 5:32PM

Thursday, July 20, 2023

On July 17, vTv Therapeutics Received Nasdaq Notice Approving Request To Extend Co's Period To Regain Compliance With Min Bid Requirement Until Dec 18
Happy Mohamed - Jul 20, 2023, 4:28PM

Thursday, June 22, 2023

Board Member at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM
Director at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM

Friday, June 16, 2023

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment For Cancer-Related Cognitive Decline
Benzinga Newsdesk - Jun 16, 2023, 8:01AM

Thursday, June 01, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jun 1, 2023, 5:39PM
Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pharma
Happy Mohamed - Jun 1, 2023, 10:49AM

Wednesday, May 24, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 24, 2023, 9:06AM
vTv Therapeutics Announces Issuance Of US Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Benzinga Newsdesk - May 24, 2023, 9:04AM

Thursday, April 20, 2023

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19
Benzinga Newsdesk - Apr 20, 2023, 8:07AM

Tuesday, March 07, 2023

HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk - Mar 7, 2023, 4:41AM

Monday, March 06, 2023

vTv Therapeutics Q4 EPS $(0.06), Inline, Sales $9.00K, Same YoY
Michael Horton - Mar 6, 2023, 5:33PM
VTv Therapeutics shares are trading higher after Cantex and the Miami Cancer Institute announced FDA clearance for a clinical trial investigating azeliragon combined with stereotactic radiosurgery for the treatment of brain metastases.
Benzinga Newsdesk - Mar 6, 2023, 8:24AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Benzinga Newsdesk - Mar 6, 2023, 8:03AM

Monday, February 27, 2023

Cantex Receives FDA 'Study May Proceed' Letter For Phase 2 Clinical Trial Of Azeliragon For Treatment Of Unmethylated Glioblastoma
Bill Haddad - Feb 27, 2023, 8:07AM

Tuesday, January 10, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jan 10, 2023, 8:05AM

Monday, January 09, 2023

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Glioblastoma
Benzinga Newsdesk - Jan 9, 2023, 8:01AM

Tuesday, December 13, 2022

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch As Chief Financial Officer Effective Immediately
Benzinga Newsdesk - Dec 13, 2022, 8:16AM

Thursday, December 01, 2022

vTv Therapeutics Board Member Makes $50K Stock Purchase
Benzinga Insights - Dec 1, 2022, 10:01AM

Thursday, November 10, 2022

vTv Therapeutics Q3 EPS $(0.05) Down From $(0.02) YoY
Michael Horton - Nov 10, 2022, 5:26PM

Friday, August 19, 2022

This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
Vandana Singh - Aug 19, 2022, 12:42PM

Wednesday, August 17, 2022

Northland Capital Markets Maintains Outperform on vTv Therapeutics, Raises Price Target to $2
Benzinga Newsdesk - Aug 17, 2022, 10:37AM

Wednesday, July 27, 2022

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Vandana Singh - Jul 27, 2022, 9:28AM
vTv Therapeutics Announces Paul Sekhri As President And Chief Executive Officer
Bill Haddad - Jul 27, 2022, 7:23AM

Monday, July 25, 2022

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Vandana Singh - Jul 25, 2022, 9:20AM
vTv Therapeutics shares are trading higher after the company announced a $10 million investment by CinRx Pharma.
Benzinga Newsdesk - Jul 25, 2022, 8:29AM
vTv Therapeutics Shares Jump On Equity Investment
Vandana Singh - Jul 25, 2022, 8:22AM
11 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 25, 2022, 8:16AM
vTv Therapeutics Announces Investment By CinRx Pharma; CinPax Acquired ~4.15M Shares Of vTv Common Stock For ~$2.41/Share
Benzinga Newsdesk - Jul 25, 2022, 7:08AM

Friday, July 08, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jul 8, 2022, 5:58PM

Wednesday, June 22, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 22, 2022, 5:42PM

Friday, June 17, 2022

vTv Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - Jun 17, 2022, 11:04AM

Tuesday, June 07, 2022

vTv Therapeutics Shares Move Higher; Co Granted Canadian Patent Titled 'TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE'
Benzinga Newsdesk - Jun 7, 2022, 10:49AM

Friday, June 03, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Jun 3, 2022, 8:08AM
Aravive Names Rudy Howard as CFO
Charles Gross - Jun 3, 2022, 7:05AM

Thursday, June 02, 2022

62 Biggest Movers From Yesterday
Lisa Levin - Jun 2, 2022, 6:10AM

Wednesday, June 01, 2022

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet
Lisa Levin - Jun 1, 2022, 2:51PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jun 1, 2022, 1:44PM
Mid-Day Market Update: Dow Dips 200 Points; Tonix Pharmaceuticals Shares Spike Higher
Lisa Levin - Jun 1, 2022, 12:17PM
44 Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Jun 1, 2022, 12:14PM
Benzinga's Brief On Trending Tickers: Salesforce, Mullen Automotive, Digital Turbine And More
AJ Fabino - Jun 1, 2022, 9:32AM
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, June 1, 2022: TSLA, GME, VTVT, ETON, KYMR
Benzinga Newsdesk - Jun 1, 2022, 8:53AM
vTv Therapeutics shares are trading higher after the company announced entry into agreements that include a $25 million investment by G42 Investments.
Benzinga Newsdesk - Jun 1, 2022, 8:51AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jun 1, 2022, 8:08AM
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
Bill Haddad - Jun 1, 2022, 6:56AM

Wednesday, May 18, 2022

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 18, 2022, 8:17AM

1
2
3
4
5
6
7
Next
17

Latest News for vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Stock (NASDAQ: VTVT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, August 11, 2023

vTv Therapeutics Q2 EPS $(0.07), Inline
Benzinga Newsdesk - Aug 11, 2023, 4:33PM

Thursday, August 10, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Aug 10, 2023, 9:06AM
Cantex Pharmaceuticals Announces Article Published In npj Breast Cancer Highlighting Potential Role Of RAGE Inhibition To Prevent Metastasis In Triple-Negative Breast Cancer
Benzinga Newsdesk - Aug 10, 2023, 8:34AM

Thursday, July 27, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jul 27, 2023, 5:32PM

Thursday, July 20, 2023

On July 17, vTv Therapeutics Received Nasdaq Notice Approving Request To Extend Co's Period To Regain Compliance With Min Bid Requirement Until Dec 18
Happy Mohamed - Jul 20, 2023, 4:28PM

Thursday, June 22, 2023

Board Member at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM
Director at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM

Friday, June 16, 2023

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment For Cancer-Related Cognitive Decline
Benzinga Newsdesk - Jun 16, 2023, 8:01AM

Thursday, June 01, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jun 1, 2023, 5:39PM
Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pharma
Happy Mohamed - Jun 1, 2023, 10:49AM

Wednesday, May 24, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 24, 2023, 9:06AM
vTv Therapeutics Announces Issuance Of US Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Benzinga Newsdesk - May 24, 2023, 9:04AM

Thursday, April 20, 2023

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19
Benzinga Newsdesk - Apr 20, 2023, 8:07AM

Tuesday, March 07, 2023

HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk - Mar 7, 2023, 4:41AM

Monday, March 06, 2023

vTv Therapeutics Q4 EPS $(0.06), Inline, Sales $9.00K, Same YoY
Michael Horton - Mar 6, 2023, 5:33PM
VTv Therapeutics shares are trading higher after Cantex and the Miami Cancer Institute announced FDA clearance for a clinical trial investigating azeliragon combined with stereotactic radiosurgery for the treatment of brain metastases.
Benzinga Newsdesk - Mar 6, 2023, 8:24AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Benzinga Newsdesk - Mar 6, 2023, 8:03AM

Monday, February 27, 2023

Cantex Receives FDA 'Study May Proceed' Letter For Phase 2 Clinical Trial Of Azeliragon For Treatment Of Unmethylated Glioblastoma
Bill Haddad - Feb 27, 2023, 8:07AM

Tuesday, January 10, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jan 10, 2023, 8:05AM

Monday, January 09, 2023

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Glioblastoma
Benzinga Newsdesk - Jan 9, 2023, 8:01AM

Tuesday, December 13, 2022

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch As Chief Financial Officer Effective Immediately
Benzinga Newsdesk - Dec 13, 2022, 8:16AM

Thursday, December 01, 2022

vTv Therapeutics Board Member Makes $50K Stock Purchase
Benzinga Insights - Dec 1, 2022, 10:01AM

Thursday, November 10, 2022

vTv Therapeutics Q3 EPS $(0.05) Down From $(0.02) YoY
Michael Horton - Nov 10, 2022, 5:26PM

Friday, August 19, 2022

This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
Vandana Singh - Aug 19, 2022, 12:42PM

Wednesday, August 17, 2022

Northland Capital Markets Maintains Outperform on vTv Therapeutics, Raises Price Target to $2
Benzinga Newsdesk - Aug 17, 2022, 10:37AM

Wednesday, July 27, 2022

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Vandana Singh - Jul 27, 2022, 9:28AM
vTv Therapeutics Announces Paul Sekhri As President And Chief Executive Officer
Bill Haddad - Jul 27, 2022, 7:23AM

Monday, July 25, 2022

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Vandana Singh - Jul 25, 2022, 9:20AM
vTv Therapeutics shares are trading higher after the company announced a $10 million investment by CinRx Pharma.
Benzinga Newsdesk - Jul 25, 2022, 8:29AM
vTv Therapeutics Shares Jump On Equity Investment
Vandana Singh - Jul 25, 2022, 8:22AM
11 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 25, 2022, 8:16AM
vTv Therapeutics Announces Investment By CinRx Pharma; CinPax Acquired ~4.15M Shares Of vTv Common Stock For ~$2.41/Share
Benzinga Newsdesk - Jul 25, 2022, 7:08AM

Friday, July 08, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jul 8, 2022, 5:58PM

Wednesday, June 22, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 22, 2022, 5:42PM

Friday, June 17, 2022

vTv Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - Jun 17, 2022, 11:04AM

Tuesday, June 07, 2022

vTv Therapeutics Shares Move Higher; Co Granted Canadian Patent Titled 'TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE'
Benzinga Newsdesk - Jun 7, 2022, 10:49AM

Friday, June 03, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Jun 3, 2022, 8:08AM
Aravive Names Rudy Howard as CFO
Charles Gross - Jun 3, 2022, 7:05AM

Thursday, June 02, 2022

62 Biggest Movers From Yesterday
Lisa Levin - Jun 2, 2022, 6:10AM

Wednesday, June 01, 2022

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet
Lisa Levin - Jun 1, 2022, 2:51PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jun 1, 2022, 1:44PM
Mid-Day Market Update: Dow Dips 200 Points; Tonix Pharmaceuticals Shares Spike Higher
Lisa Levin - Jun 1, 2022, 12:17PM
44 Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Jun 1, 2022, 12:14PM
Benzinga's Brief On Trending Tickers: Salesforce, Mullen Automotive, Digital Turbine And More
AJ Fabino - Jun 1, 2022, 9:32AM
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, June 1, 2022: TSLA, GME, VTVT, ETON, KYMR
Benzinga Newsdesk - Jun 1, 2022, 8:53AM
vTv Therapeutics shares are trading higher after the company announced entry into agreements that include a $25 million investment by G42 Investments.
Benzinga Newsdesk - Jun 1, 2022, 8:51AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jun 1, 2022, 8:08AM
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
Bill Haddad - Jun 1, 2022, 6:56AM

Wednesday, May 18, 2022

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 18, 2022, 8:17AM

1
2
3
4
5
6
7
Next
17

Latest News for vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Stock (NASDAQ: VTVT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, August 11, 2023

vTv Therapeutics Q2 EPS $(0.07), Inline
Benzinga Newsdesk - Aug 11, 2023, 4:33PM

Thursday, August 10, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Aug 10, 2023, 9:06AM
Cantex Pharmaceuticals Announces Article Published In npj Breast Cancer Highlighting Potential Role Of RAGE Inhibition To Prevent Metastasis In Triple-Negative Breast Cancer
Benzinga Newsdesk - Aug 10, 2023, 8:34AM

Thursday, July 27, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jul 27, 2023, 5:32PM

Thursday, July 20, 2023

On July 17, vTv Therapeutics Received Nasdaq Notice Approving Request To Extend Co's Period To Regain Compliance With Min Bid Requirement Until Dec 18
Happy Mohamed - Jul 20, 2023, 4:28PM

Thursday, June 22, 2023

Board Member at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM
Director at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM

Friday, June 16, 2023

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment For Cancer-Related Cognitive Decline
Benzinga Newsdesk - Jun 16, 2023, 8:01AM

Thursday, June 01, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jun 1, 2023, 5:39PM
Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pharma
Happy Mohamed - Jun 1, 2023, 10:49AM

Wednesday, May 24, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 24, 2023, 9:06AM
vTv Therapeutics Announces Issuance Of US Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Benzinga Newsdesk - May 24, 2023, 9:04AM

Thursday, April 20, 2023

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19
Benzinga Newsdesk - Apr 20, 2023, 8:07AM

Tuesday, March 07, 2023

HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk - Mar 7, 2023, 4:41AM

Monday, March 06, 2023

vTv Therapeutics Q4 EPS $(0.06), Inline, Sales $9.00K, Same YoY
Michael Horton - Mar 6, 2023, 5:33PM
VTv Therapeutics shares are trading higher after Cantex and the Miami Cancer Institute announced FDA clearance for a clinical trial investigating azeliragon combined with stereotactic radiosurgery for the treatment of brain metastases.
Benzinga Newsdesk - Mar 6, 2023, 8:24AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Benzinga Newsdesk - Mar 6, 2023, 8:03AM

Monday, February 27, 2023

Cantex Receives FDA 'Study May Proceed' Letter For Phase 2 Clinical Trial Of Azeliragon For Treatment Of Unmethylated Glioblastoma
Bill Haddad - Feb 27, 2023, 8:07AM

Tuesday, January 10, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jan 10, 2023, 8:05AM

Monday, January 09, 2023

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Glioblastoma
Benzinga Newsdesk - Jan 9, 2023, 8:01AM

Tuesday, December 13, 2022

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch As Chief Financial Officer Effective Immediately
Benzinga Newsdesk - Dec 13, 2022, 8:16AM

Thursday, December 01, 2022

vTv Therapeutics Board Member Makes $50K Stock Purchase
Benzinga Insights - Dec 1, 2022, 10:01AM

Thursday, November 10, 2022

vTv Therapeutics Q3 EPS $(0.05) Down From $(0.02) YoY
Michael Horton - Nov 10, 2022, 5:26PM

Friday, August 19, 2022

This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
Vandana Singh - Aug 19, 2022, 12:42PM

Wednesday, August 17, 2022

Northland Capital Markets Maintains Outperform on vTv Therapeutics, Raises Price Target to $2
Benzinga Newsdesk - Aug 17, 2022, 10:37AM

Wednesday, July 27, 2022

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Vandana Singh - Jul 27, 2022, 9:28AM
vTv Therapeutics Announces Paul Sekhri As President And Chief Executive Officer
Bill Haddad - Jul 27, 2022, 7:23AM

Monday, July 25, 2022

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Vandana Singh - Jul 25, 2022, 9:20AM
vTv Therapeutics shares are trading higher after the company announced a $10 million investment by CinRx Pharma.
Benzinga Newsdesk - Jul 25, 2022, 8:29AM
vTv Therapeutics Shares Jump On Equity Investment
Vandana Singh - Jul 25, 2022, 8:22AM
11 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 25, 2022, 8:16AM
vTv Therapeutics Announces Investment By CinRx Pharma; CinPax Acquired ~4.15M Shares Of vTv Common Stock For ~$2.41/Share
Benzinga Newsdesk - Jul 25, 2022, 7:08AM

Friday, July 08, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jul 8, 2022, 5:58PM

Wednesday, June 22, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 22, 2022, 5:42PM

Friday, June 17, 2022

vTv Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - Jun 17, 2022, 11:04AM

Tuesday, June 07, 2022

vTv Therapeutics Shares Move Higher; Co Granted Canadian Patent Titled 'TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE'
Benzinga Newsdesk - Jun 7, 2022, 10:49AM

Friday, June 03, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Jun 3, 2022, 8:08AM
Aravive Names Rudy Howard as CFO
Charles Gross - Jun 3, 2022, 7:05AM

Thursday, June 02, 2022

62 Biggest Movers From Yesterday
Lisa Levin - Jun 2, 2022, 6:10AM

Wednesday, June 01, 2022

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet
Lisa Levin - Jun 1, 2022, 2:51PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jun 1, 2022, 1:44PM
Mid-Day Market Update: Dow Dips 200 Points; Tonix Pharmaceuticals Shares Spike Higher
Lisa Levin - Jun 1, 2022, 12:17PM
44 Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Jun 1, 2022, 12:14PM
Benzinga's Brief On Trending Tickers: Salesforce, Mullen Automotive, Digital Turbine And More
AJ Fabino - Jun 1, 2022, 9:32AM
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, June 1, 2022: TSLA, GME, VTVT, ETON, KYMR
Benzinga Newsdesk - Jun 1, 2022, 8:53AM
vTv Therapeutics shares are trading higher after the company announced entry into agreements that include a $25 million investment by G42 Investments.
Benzinga Newsdesk - Jun 1, 2022, 8:51AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jun 1, 2022, 8:08AM
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
Bill Haddad - Jun 1, 2022, 6:56AM

Wednesday, May 18, 2022

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 18, 2022, 8:17AM

1
2
3
4
5
6
7
Next
17

Latest News for vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Stock (NASDAQ: VTVT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, August 11, 2023

vTv Therapeutics Q2 EPS $(0.07), Inline
Benzinga Newsdesk - Aug 11, 2023, 4:33PM

Thursday, August 10, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Aug 10, 2023, 9:06AM
Cantex Pharmaceuticals Announces Article Published In npj Breast Cancer Highlighting Potential Role Of RAGE Inhibition To Prevent Metastasis In Triple-Negative Breast Cancer
Benzinga Newsdesk - Aug 10, 2023, 8:34AM

Thursday, July 27, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jul 27, 2023, 5:32PM

Thursday, July 20, 2023

On July 17, vTv Therapeutics Received Nasdaq Notice Approving Request To Extend Co's Period To Regain Compliance With Min Bid Requirement Until Dec 18
Happy Mohamed - Jul 20, 2023, 4:28PM

Thursday, June 22, 2023

Board Member at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM
Director at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM

Friday, June 16, 2023

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment For Cancer-Related Cognitive Decline
Benzinga Newsdesk - Jun 16, 2023, 8:01AM

Thursday, June 01, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jun 1, 2023, 5:39PM
Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pharma
Happy Mohamed - Jun 1, 2023, 10:49AM

Wednesday, May 24, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 24, 2023, 9:06AM
vTv Therapeutics Announces Issuance Of US Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Benzinga Newsdesk - May 24, 2023, 9:04AM

Thursday, April 20, 2023

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19
Benzinga Newsdesk - Apr 20, 2023, 8:07AM

Tuesday, March 07, 2023

HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk - Mar 7, 2023, 4:41AM

Monday, March 06, 2023

vTv Therapeutics Q4 EPS $(0.06), Inline, Sales $9.00K, Same YoY
Michael Horton - Mar 6, 2023, 5:33PM
VTv Therapeutics shares are trading higher after Cantex and the Miami Cancer Institute announced FDA clearance for a clinical trial investigating azeliragon combined with stereotactic radiosurgery for the treatment of brain metastases.
Benzinga Newsdesk - Mar 6, 2023, 8:24AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Benzinga Newsdesk - Mar 6, 2023, 8:03AM

Monday, February 27, 2023

Cantex Receives FDA 'Study May Proceed' Letter For Phase 2 Clinical Trial Of Azeliragon For Treatment Of Unmethylated Glioblastoma
Bill Haddad - Feb 27, 2023, 8:07AM

Tuesday, January 10, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jan 10, 2023, 8:05AM

Monday, January 09, 2023

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Glioblastoma
Benzinga Newsdesk - Jan 9, 2023, 8:01AM

Tuesday, December 13, 2022

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch As Chief Financial Officer Effective Immediately
Benzinga Newsdesk - Dec 13, 2022, 8:16AM

Thursday, December 01, 2022

vTv Therapeutics Board Member Makes $50K Stock Purchase
Benzinga Insights - Dec 1, 2022, 10:01AM

Thursday, November 10, 2022

vTv Therapeutics Q3 EPS $(0.05) Down From $(0.02) YoY
Michael Horton - Nov 10, 2022, 5:26PM

Friday, August 19, 2022

This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
Vandana Singh - Aug 19, 2022, 12:42PM

Wednesday, August 17, 2022

Northland Capital Markets Maintains Outperform on vTv Therapeutics, Raises Price Target to $2
Benzinga Newsdesk - Aug 17, 2022, 10:37AM

Wednesday, July 27, 2022

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Vandana Singh - Jul 27, 2022, 9:28AM
vTv Therapeutics Announces Paul Sekhri As President And Chief Executive Officer
Bill Haddad - Jul 27, 2022, 7:23AM

Monday, July 25, 2022

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Vandana Singh - Jul 25, 2022, 9:20AM
vTv Therapeutics shares are trading higher after the company announced a $10 million investment by CinRx Pharma.
Benzinga Newsdesk - Jul 25, 2022, 8:29AM
vTv Therapeutics Shares Jump On Equity Investment
Vandana Singh - Jul 25, 2022, 8:22AM
11 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 25, 2022, 8:16AM
vTv Therapeutics Announces Investment By CinRx Pharma; CinPax Acquired ~4.15M Shares Of vTv Common Stock For ~$2.41/Share
Benzinga Newsdesk - Jul 25, 2022, 7:08AM

Friday, July 08, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jul 8, 2022, 5:58PM

Wednesday, June 22, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 22, 2022, 5:42PM

Friday, June 17, 2022

vTv Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - Jun 17, 2022, 11:04AM

Tuesday, June 07, 2022

vTv Therapeutics Shares Move Higher; Co Granted Canadian Patent Titled 'TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE'
Benzinga Newsdesk - Jun 7, 2022, 10:49AM

Friday, June 03, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Jun 3, 2022, 8:08AM
Aravive Names Rudy Howard as CFO
Charles Gross - Jun 3, 2022, 7:05AM

Thursday, June 02, 2022

62 Biggest Movers From Yesterday
Lisa Levin - Jun 2, 2022, 6:10AM

Wednesday, June 01, 2022

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet
Lisa Levin - Jun 1, 2022, 2:51PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jun 1, 2022, 1:44PM
Mid-Day Market Update: Dow Dips 200 Points; Tonix Pharmaceuticals Shares Spike Higher
Lisa Levin - Jun 1, 2022, 12:17PM
44 Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Jun 1, 2022, 12:14PM
Benzinga's Brief On Trending Tickers: Salesforce, Mullen Automotive, Digital Turbine And More
AJ Fabino - Jun 1, 2022, 9:32AM
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, June 1, 2022: TSLA, GME, VTVT, ETON, KYMR
Benzinga Newsdesk - Jun 1, 2022, 8:53AM
vTv Therapeutics shares are trading higher after the company announced entry into agreements that include a $25 million investment by G42 Investments.
Benzinga Newsdesk - Jun 1, 2022, 8:51AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jun 1, 2022, 8:08AM
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
Bill Haddad - Jun 1, 2022, 6:56AM

Wednesday, May 18, 2022

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 18, 2022, 8:17AM

1
2
3
4
5
6
7
Next
17

Latest News for vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Stock (NASDAQ: VTVT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, August 11, 2023

vTv Therapeutics Q2 EPS $(0.07), Inline
Benzinga Newsdesk - Aug 11, 2023, 4:33PM

Thursday, August 10, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Aug 10, 2023, 9:06AM
Cantex Pharmaceuticals Announces Article Published In npj Breast Cancer Highlighting Potential Role Of RAGE Inhibition To Prevent Metastasis In Triple-Negative Breast Cancer
Benzinga Newsdesk - Aug 10, 2023, 8:34AM

Thursday, July 27, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jul 27, 2023, 5:32PM

Thursday, July 20, 2023

On July 17, vTv Therapeutics Received Nasdaq Notice Approving Request To Extend Co's Period To Regain Compliance With Min Bid Requirement Until Dec 18
Happy Mohamed - Jul 20, 2023, 4:28PM

Thursday, June 22, 2023

Board Member at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM
Director at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM

Friday, June 16, 2023

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment For Cancer-Related Cognitive Decline
Benzinga Newsdesk - Jun 16, 2023, 8:01AM

Thursday, June 01, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jun 1, 2023, 5:39PM
Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pharma
Happy Mohamed - Jun 1, 2023, 10:49AM

Wednesday, May 24, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 24, 2023, 9:06AM
vTv Therapeutics Announces Issuance Of US Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Benzinga Newsdesk - May 24, 2023, 9:04AM

Thursday, April 20, 2023

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19
Benzinga Newsdesk - Apr 20, 2023, 8:07AM

Tuesday, March 07, 2023

HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk - Mar 7, 2023, 4:41AM

Monday, March 06, 2023

vTv Therapeutics Q4 EPS $(0.06), Inline, Sales $9.00K, Same YoY
Michael Horton - Mar 6, 2023, 5:33PM
VTv Therapeutics shares are trading higher after Cantex and the Miami Cancer Institute announced FDA clearance for a clinical trial investigating azeliragon combined with stereotactic radiosurgery for the treatment of brain metastases.
Benzinga Newsdesk - Mar 6, 2023, 8:24AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Benzinga Newsdesk - Mar 6, 2023, 8:03AM

Monday, February 27, 2023

Cantex Receives FDA 'Study May Proceed' Letter For Phase 2 Clinical Trial Of Azeliragon For Treatment Of Unmethylated Glioblastoma
Bill Haddad - Feb 27, 2023, 8:07AM

Tuesday, January 10, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jan 10, 2023, 8:05AM

Monday, January 09, 2023

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Glioblastoma
Benzinga Newsdesk - Jan 9, 2023, 8:01AM

Tuesday, December 13, 2022

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch As Chief Financial Officer Effective Immediately
Benzinga Newsdesk - Dec 13, 2022, 8:16AM

Thursday, December 01, 2022

vTv Therapeutics Board Member Makes $50K Stock Purchase
Benzinga Insights - Dec 1, 2022, 10:01AM

Thursday, November 10, 2022

vTv Therapeutics Q3 EPS $(0.05) Down From $(0.02) YoY
Michael Horton - Nov 10, 2022, 5:26PM

Friday, August 19, 2022

This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
Vandana Singh - Aug 19, 2022, 12:42PM

Wednesday, August 17, 2022

Northland Capital Markets Maintains Outperform on vTv Therapeutics, Raises Price Target to $2
Benzinga Newsdesk - Aug 17, 2022, 10:37AM

Wednesday, July 27, 2022

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Vandana Singh - Jul 27, 2022, 9:28AM
vTv Therapeutics Announces Paul Sekhri As President And Chief Executive Officer
Bill Haddad - Jul 27, 2022, 7:23AM

Monday, July 25, 2022

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Vandana Singh - Jul 25, 2022, 9:20AM
vTv Therapeutics shares are trading higher after the company announced a $10 million investment by CinRx Pharma.
Benzinga Newsdesk - Jul 25, 2022, 8:29AM
vTv Therapeutics Shares Jump On Equity Investment
Vandana Singh - Jul 25, 2022, 8:22AM
11 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 25, 2022, 8:16AM
vTv Therapeutics Announces Investment By CinRx Pharma; CinPax Acquired ~4.15M Shares Of vTv Common Stock For ~$2.41/Share
Benzinga Newsdesk - Jul 25, 2022, 7:08AM

Friday, July 08, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jul 8, 2022, 5:58PM

Wednesday, June 22, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 22, 2022, 5:42PM

Friday, June 17, 2022

vTv Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - Jun 17, 2022, 11:04AM

Tuesday, June 07, 2022

vTv Therapeutics Shares Move Higher; Co Granted Canadian Patent Titled 'TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE'
Benzinga Newsdesk - Jun 7, 2022, 10:49AM

Friday, June 03, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Jun 3, 2022, 8:08AM
Aravive Names Rudy Howard as CFO
Charles Gross - Jun 3, 2022, 7:05AM

Thursday, June 02, 2022

62 Biggest Movers From Yesterday
Lisa Levin - Jun 2, 2022, 6:10AM

Wednesday, June 01, 2022

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet
Lisa Levin - Jun 1, 2022, 2:51PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jun 1, 2022, 1:44PM
Mid-Day Market Update: Dow Dips 200 Points; Tonix Pharmaceuticals Shares Spike Higher
Lisa Levin - Jun 1, 2022, 12:17PM
44 Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Jun 1, 2022, 12:14PM
Benzinga's Brief On Trending Tickers: Salesforce, Mullen Automotive, Digital Turbine And More
AJ Fabino - Jun 1, 2022, 9:32AM
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, June 1, 2022: TSLA, GME, VTVT, ETON, KYMR
Benzinga Newsdesk - Jun 1, 2022, 8:53AM
vTv Therapeutics shares are trading higher after the company announced entry into agreements that include a $25 million investment by G42 Investments.
Benzinga Newsdesk - Jun 1, 2022, 8:51AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jun 1, 2022, 8:08AM
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
Bill Haddad - Jun 1, 2022, 6:56AM

Wednesday, May 18, 2022

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 18, 2022, 8:17AM

1
2
3
4
5
6
7
Next
17

Latest News for vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Stock (NASDAQ: VTVT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, August 11, 2023

vTv Therapeutics Q2 EPS $(0.07), Inline
Benzinga Newsdesk - Aug 11, 2023, 4:33PM

Thursday, August 10, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Aug 10, 2023, 9:06AM
Cantex Pharmaceuticals Announces Article Published In npj Breast Cancer Highlighting Potential Role Of RAGE Inhibition To Prevent Metastasis In Triple-Negative Breast Cancer
Benzinga Newsdesk - Aug 10, 2023, 8:34AM

Thursday, July 27, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jul 27, 2023, 5:32PM

Thursday, July 20, 2023

On July 17, vTv Therapeutics Received Nasdaq Notice Approving Request To Extend Co's Period To Regain Compliance With Min Bid Requirement Until Dec 18
Happy Mohamed - Jul 20, 2023, 4:28PM

Thursday, June 22, 2023

Board Member at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM
Director at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM

Friday, June 16, 2023

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment For Cancer-Related Cognitive Decline
Benzinga Newsdesk - Jun 16, 2023, 8:01AM

Thursday, June 01, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jun 1, 2023, 5:39PM
Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pharma
Happy Mohamed - Jun 1, 2023, 10:49AM

Wednesday, May 24, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 24, 2023, 9:06AM
vTv Therapeutics Announces Issuance Of US Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Benzinga Newsdesk - May 24, 2023, 9:04AM

Thursday, April 20, 2023

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19
Benzinga Newsdesk - Apr 20, 2023, 8:07AM

Tuesday, March 07, 2023

HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk - Mar 7, 2023, 4:41AM

Monday, March 06, 2023

vTv Therapeutics Q4 EPS $(0.06), Inline, Sales $9.00K, Same YoY
Michael Horton - Mar 6, 2023, 5:33PM
VTv Therapeutics shares are trading higher after Cantex and the Miami Cancer Institute announced FDA clearance for a clinical trial investigating azeliragon combined with stereotactic radiosurgery for the treatment of brain metastases.
Benzinga Newsdesk - Mar 6, 2023, 8:24AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Benzinga Newsdesk - Mar 6, 2023, 8:03AM

Monday, February 27, 2023

Cantex Receives FDA 'Study May Proceed' Letter For Phase 2 Clinical Trial Of Azeliragon For Treatment Of Unmethylated Glioblastoma
Bill Haddad - Feb 27, 2023, 8:07AM

Tuesday, January 10, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jan 10, 2023, 8:05AM

Monday, January 09, 2023

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Glioblastoma
Benzinga Newsdesk - Jan 9, 2023, 8:01AM

Tuesday, December 13, 2022

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch As Chief Financial Officer Effective Immediately
Benzinga Newsdesk - Dec 13, 2022, 8:16AM

Thursday, December 01, 2022

vTv Therapeutics Board Member Makes $50K Stock Purchase
Benzinga Insights - Dec 1, 2022, 10:01AM

Thursday, November 10, 2022

vTv Therapeutics Q3 EPS $(0.05) Down From $(0.02) YoY
Michael Horton - Nov 10, 2022, 5:26PM

Friday, August 19, 2022

This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
Vandana Singh - Aug 19, 2022, 12:42PM

Wednesday, August 17, 2022

Northland Capital Markets Maintains Outperform on vTv Therapeutics, Raises Price Target to $2
Benzinga Newsdesk - Aug 17, 2022, 10:37AM

Wednesday, July 27, 2022

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Vandana Singh - Jul 27, 2022, 9:28AM
vTv Therapeutics Announces Paul Sekhri As President And Chief Executive Officer
Bill Haddad - Jul 27, 2022, 7:23AM

Monday, July 25, 2022

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Vandana Singh - Jul 25, 2022, 9:20AM
vTv Therapeutics shares are trading higher after the company announced a $10 million investment by CinRx Pharma.
Benzinga Newsdesk - Jul 25, 2022, 8:29AM
vTv Therapeutics Shares Jump On Equity Investment
Vandana Singh - Jul 25, 2022, 8:22AM
11 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 25, 2022, 8:16AM
vTv Therapeutics Announces Investment By CinRx Pharma; CinPax Acquired ~4.15M Shares Of vTv Common Stock For ~$2.41/Share
Benzinga Newsdesk - Jul 25, 2022, 7:08AM

Friday, July 08, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jul 8, 2022, 5:58PM

Wednesday, June 22, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 22, 2022, 5:42PM

Friday, June 17, 2022

vTv Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - Jun 17, 2022, 11:04AM

Tuesday, June 07, 2022

vTv Therapeutics Shares Move Higher; Co Granted Canadian Patent Titled 'TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE'
Benzinga Newsdesk - Jun 7, 2022, 10:49AM

Friday, June 03, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Jun 3, 2022, 8:08AM
Aravive Names Rudy Howard as CFO
Charles Gross - Jun 3, 2022, 7:05AM

Thursday, June 02, 2022

62 Biggest Movers From Yesterday
Lisa Levin - Jun 2, 2022, 6:10AM

Wednesday, June 01, 2022

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet
Lisa Levin - Jun 1, 2022, 2:51PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jun 1, 2022, 1:44PM
Mid-Day Market Update: Dow Dips 200 Points; Tonix Pharmaceuticals Shares Spike Higher
Lisa Levin - Jun 1, 2022, 12:17PM
44 Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Jun 1, 2022, 12:14PM
Benzinga's Brief On Trending Tickers: Salesforce, Mullen Automotive, Digital Turbine And More
AJ Fabino - Jun 1, 2022, 9:32AM
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, June 1, 2022: TSLA, GME, VTVT, ETON, KYMR
Benzinga Newsdesk - Jun 1, 2022, 8:53AM
vTv Therapeutics shares are trading higher after the company announced entry into agreements that include a $25 million investment by G42 Investments.
Benzinga Newsdesk - Jun 1, 2022, 8:51AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jun 1, 2022, 8:08AM
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
Bill Haddad - Jun 1, 2022, 6:56AM

Wednesday, May 18, 2022

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 18, 2022, 8:17AM

1
2
3
4
5
6
7
Next
17

Latest News for vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Stock (NASDAQ: VTVT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, August 11, 2023

vTv Therapeutics Q2 EPS $(0.07), Inline
Benzinga Newsdesk - Aug 11, 2023, 4:33PM

Thursday, August 10, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Aug 10, 2023, 9:06AM
Cantex Pharmaceuticals Announces Article Published In npj Breast Cancer Highlighting Potential Role Of RAGE Inhibition To Prevent Metastasis In Triple-Negative Breast Cancer
Benzinga Newsdesk - Aug 10, 2023, 8:34AM

Thursday, July 27, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jul 27, 2023, 5:32PM

Thursday, July 20, 2023

On July 17, vTv Therapeutics Received Nasdaq Notice Approving Request To Extend Co's Period To Regain Compliance With Min Bid Requirement Until Dec 18
Happy Mohamed - Jul 20, 2023, 4:28PM

Thursday, June 22, 2023

Board Member at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM
Director at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM

Friday, June 16, 2023

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment For Cancer-Related Cognitive Decline
Benzinga Newsdesk - Jun 16, 2023, 8:01AM

Thursday, June 01, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jun 1, 2023, 5:39PM
Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pharma
Happy Mohamed - Jun 1, 2023, 10:49AM

Wednesday, May 24, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 24, 2023, 9:06AM
vTv Therapeutics Announces Issuance Of US Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Benzinga Newsdesk - May 24, 2023, 9:04AM

Thursday, April 20, 2023

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19
Benzinga Newsdesk - Apr 20, 2023, 8:07AM

Tuesday, March 07, 2023

HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk - Mar 7, 2023, 4:41AM

Monday, March 06, 2023

vTv Therapeutics Q4 EPS $(0.06), Inline, Sales $9.00K, Same YoY
Michael Horton - Mar 6, 2023, 5:33PM
VTv Therapeutics shares are trading higher after Cantex and the Miami Cancer Institute announced FDA clearance for a clinical trial investigating azeliragon combined with stereotactic radiosurgery for the treatment of brain metastases.
Benzinga Newsdesk - Mar 6, 2023, 8:24AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Benzinga Newsdesk - Mar 6, 2023, 8:03AM

Monday, February 27, 2023

Cantex Receives FDA 'Study May Proceed' Letter For Phase 2 Clinical Trial Of Azeliragon For Treatment Of Unmethylated Glioblastoma
Bill Haddad - Feb 27, 2023, 8:07AM

Tuesday, January 10, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jan 10, 2023, 8:05AM

Monday, January 09, 2023

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Glioblastoma
Benzinga Newsdesk - Jan 9, 2023, 8:01AM

Tuesday, December 13, 2022

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch As Chief Financial Officer Effective Immediately
Benzinga Newsdesk - Dec 13, 2022, 8:16AM

Thursday, December 01, 2022

vTv Therapeutics Board Member Makes $50K Stock Purchase
Benzinga Insights - Dec 1, 2022, 10:01AM

Thursday, November 10, 2022

vTv Therapeutics Q3 EPS $(0.05) Down From $(0.02) YoY
Michael Horton - Nov 10, 2022, 5:26PM

Friday, August 19, 2022

This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
Vandana Singh - Aug 19, 2022, 12:42PM

Wednesday, August 17, 2022

Northland Capital Markets Maintains Outperform on vTv Therapeutics, Raises Price Target to $2
Benzinga Newsdesk - Aug 17, 2022, 10:37AM

Wednesday, July 27, 2022

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Vandana Singh - Jul 27, 2022, 9:28AM
vTv Therapeutics Announces Paul Sekhri As President And Chief Executive Officer
Bill Haddad - Jul 27, 2022, 7:23AM

Monday, July 25, 2022

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Vandana Singh - Jul 25, 2022, 9:20AM
vTv Therapeutics shares are trading higher after the company announced a $10 million investment by CinRx Pharma.
Benzinga Newsdesk - Jul 25, 2022, 8:29AM
vTv Therapeutics Shares Jump On Equity Investment
Vandana Singh - Jul 25, 2022, 8:22AM
11 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 25, 2022, 8:16AM
vTv Therapeutics Announces Investment By CinRx Pharma; CinPax Acquired ~4.15M Shares Of vTv Common Stock For ~$2.41/Share
Benzinga Newsdesk - Jul 25, 2022, 7:08AM

Friday, July 08, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jul 8, 2022, 5:58PM

Wednesday, June 22, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 22, 2022, 5:42PM

Friday, June 17, 2022

vTv Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - Jun 17, 2022, 11:04AM

Tuesday, June 07, 2022

vTv Therapeutics Shares Move Higher; Co Granted Canadian Patent Titled 'TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE'
Benzinga Newsdesk - Jun 7, 2022, 10:49AM

Friday, June 03, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Jun 3, 2022, 8:08AM
Aravive Names Rudy Howard as CFO
Charles Gross - Jun 3, 2022, 7:05AM

Thursday, June 02, 2022

62 Biggest Movers From Yesterday
Lisa Levin - Jun 2, 2022, 6:10AM

Wednesday, June 01, 2022

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet
Lisa Levin - Jun 1, 2022, 2:51PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jun 1, 2022, 1:44PM
Mid-Day Market Update: Dow Dips 200 Points; Tonix Pharmaceuticals Shares Spike Higher
Lisa Levin - Jun 1, 2022, 12:17PM
44 Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Jun 1, 2022, 12:14PM
Benzinga's Brief On Trending Tickers: Salesforce, Mullen Automotive, Digital Turbine And More
AJ Fabino - Jun 1, 2022, 9:32AM
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, June 1, 2022: TSLA, GME, VTVT, ETON, KYMR
Benzinga Newsdesk - Jun 1, 2022, 8:53AM
vTv Therapeutics shares are trading higher after the company announced entry into agreements that include a $25 million investment by G42 Investments.
Benzinga Newsdesk - Jun 1, 2022, 8:51AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jun 1, 2022, 8:08AM
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
Bill Haddad - Jun 1, 2022, 6:56AM

Wednesday, May 18, 2022

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 18, 2022, 8:17AM

1
2
3
4
5
6
7
Next
17

Latest News for vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Stock (NASDAQ: VTVT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, August 11, 2023

vTv Therapeutics Q2 EPS $(0.07), Inline
Benzinga Newsdesk - Aug 11, 2023, 4:33PM

Thursday, August 10, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Aug 10, 2023, 9:06AM
Cantex Pharmaceuticals Announces Article Published In npj Breast Cancer Highlighting Potential Role Of RAGE Inhibition To Prevent Metastasis In Triple-Negative Breast Cancer
Benzinga Newsdesk - Aug 10, 2023, 8:34AM

Thursday, July 27, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jul 27, 2023, 5:32PM

Thursday, July 20, 2023

On July 17, vTv Therapeutics Received Nasdaq Notice Approving Request To Extend Co's Period To Regain Compliance With Min Bid Requirement Until Dec 18
Happy Mohamed - Jul 20, 2023, 4:28PM

Thursday, June 22, 2023

Board Member at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM
Director at vTv Therapeutics Acquires Company Stock Options Worth 75,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM

Friday, June 16, 2023

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment For Cancer-Related Cognitive Decline
Benzinga Newsdesk - Jun 16, 2023, 8:01AM

Thursday, June 01, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jun 1, 2023, 5:39PM
Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pharma
Happy Mohamed - Jun 1, 2023, 10:49AM

Wednesday, May 24, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 24, 2023, 9:06AM
vTv Therapeutics Announces Issuance Of US Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Benzinga Newsdesk - May 24, 2023, 9:04AM

Thursday, April 20, 2023

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19
Benzinga Newsdesk - Apr 20, 2023, 8:07AM

Tuesday, March 07, 2023

HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk - Mar 7, 2023, 4:41AM

Monday, March 06, 2023

vTv Therapeutics Q4 EPS $(0.06), Inline, Sales $9.00K, Same YoY
Michael Horton - Mar 6, 2023, 5:33PM
VTv Therapeutics shares are trading higher after Cantex and the Miami Cancer Institute announced FDA clearance for a clinical trial investigating azeliragon combined with stereotactic radiosurgery for the treatment of brain metastases.
Benzinga Newsdesk - Mar 6, 2023, 8:24AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Benzinga Newsdesk - Mar 6, 2023, 8:03AM

Monday, February 27, 2023

Cantex Receives FDA 'Study May Proceed' Letter For Phase 2 Clinical Trial Of Azeliragon For Treatment Of Unmethylated Glioblastoma
Bill Haddad - Feb 27, 2023, 8:07AM

Tuesday, January 10, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jan 10, 2023, 8:05AM

Monday, January 09, 2023

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Glioblastoma
Benzinga Newsdesk - Jan 9, 2023, 8:01AM

Tuesday, December 13, 2022

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch As Chief Financial Officer Effective Immediately
Benzinga Newsdesk - Dec 13, 2022, 8:16AM

Thursday, December 01, 2022

vTv Therapeutics Board Member Makes $50K Stock Purchase
Benzinga Insights - Dec 1, 2022, 10:01AM

Thursday, November 10, 2022

vTv Therapeutics Q3 EPS $(0.05) Down From $(0.02) YoY
Michael Horton - Nov 10, 2022, 5:26PM

Friday, August 19, 2022

This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
Vandana Singh - Aug 19, 2022, 12:42PM

Wednesday, August 17, 2022

Northland Capital Markets Maintains Outperform on vTv Therapeutics, Raises Price Target to $2
Benzinga Newsdesk - Aug 17, 2022, 10:37AM

Wednesday, July 27, 2022

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Vandana Singh - Jul 27, 2022, 9:28AM
vTv Therapeutics Announces Paul Sekhri As President And Chief Executive Officer
Bill Haddad - Jul 27, 2022, 7:23AM

Monday, July 25, 2022

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Vandana Singh - Jul 25, 2022, 9:20AM
vTv Therapeutics shares are trading higher after the company announced a $10 million investment by CinRx Pharma.
Benzinga Newsdesk - Jul 25, 2022, 8:29AM
vTv Therapeutics Shares Jump On Equity Investment
Vandana Singh - Jul 25, 2022, 8:22AM
11 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 25, 2022, 8:16AM
vTv Therapeutics Announces Investment By CinRx Pharma; CinPax Acquired ~4.15M Shares Of vTv Common Stock For ~$2.41/Share
Benzinga Newsdesk - Jul 25, 2022, 7:08AM

Friday, July 08, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jul 8, 2022, 5:58PM

Wednesday, June 22, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 22, 2022, 5:42PM

Friday, June 17, 2022

vTv Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - Jun 17, 2022, 11:04AM

Tuesday, June 07, 2022

vTv Therapeutics Shares Move Higher; Co Granted Canadian Patent Titled 'TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE'
Benzinga Newsdesk - Jun 7, 2022, 10:49AM

Friday, June 03, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Jun 3, 2022, 8:08AM
Aravive Names Rudy Howard as CFO
Charles Gross - Jun 3, 2022, 7:05AM

Thursday, June 02, 2022

62 Biggest Movers From Yesterday
Lisa Levin - Jun 2, 2022, 6:10AM

Wednesday, June 01, 2022

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet
Lisa Levin - Jun 1, 2022, 2:51PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jun 1, 2022, 1:44PM
Mid-Day Market Update: Dow Dips 200 Points; Tonix Pharmaceuticals Shares Spike Higher
Lisa Levin - Jun 1, 2022, 12:17PM
44 Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Jun 1, 2022, 12:14PM
Benzinga's Brief On Trending Tickers: Salesforce, Mullen Automotive, Digital Turbine And More
AJ Fabino - Jun 1, 2022, 9:32AM
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, June 1, 2022: TSLA, GME, VTVT, ETON, KYMR
Benzinga Newsdesk - Jun 1, 2022, 8:53AM
vTv Therapeutics shares are trading higher after the company announced entry into agreements that include a $25 million investment by G42 Investments.
Benzinga Newsdesk - Jun 1, 2022, 8:51AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jun 1, 2022, 8:08AM
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
Bill Haddad - Jun 1, 2022, 6:56AM

Wednesday, May 18, 2022

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - May 18, 2022, 8:17AM

1
2
3
4
5
6
7
Next
17

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2023 Benzinga | All Rights Reserved